These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21547395)

  • 1. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
    Rudek MA; New P; Mikkelsen T; Phuphanich S; Alavi JB; Nabors LB; Piantadosi S; Fisher JD; Grossman SA
    J Neurooncol; 2011 Nov; 105(2):375-81. PubMed ID: 21547395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
    Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
    Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
    Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
    J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
    J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
    Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
    Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD;
    Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
    Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
    J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
    Phuphanich S; Baker SD; Grossman SA; Carson KA; Gilbert MR; Fisher JD; Carducci MA
    Neuro Oncol; 2005 Apr; 7(2):177-82. PubMed ID: 15831235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of terameprocol in patients with recurrent high-grade glioma.
    Grossman SA; Ye X; Peereboom D; Rosenfeld MR; Mikkelsen T; Supko JG; Desideri S;
    Neuro Oncol; 2012 Apr; 14(4):511-7. PubMed ID: 22323663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
    Grossman SA; Carson KA; Batchelor TT; Lesser G; Mikkelsen T; Alavi JB; Phuphanich S; Hammour T; Fisher JD; Supko JG
    Clin Cancer Res; 2006 Sep; 12(17):5174-81. PubMed ID: 16951236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
    Nghiemphu PL; Lai A; Green RM; Reardon DA; Cloughesy T
    J Neurooncol; 2012 Nov; 110(2):245-50. PubMed ID: 22918789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
    Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.